Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers

BACKGROUND: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) including abiraterone. The relationship between PTEN loss and docetaxel sensiti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur Urol Oncol
Egile Nagusiak: Rescigno, Pasquale, Lorente, David, Dolling, David, Ferraldeschi, Roberta, Rodrigues, Daniel Nava, Riisnaes, Ruth, Miranda, Susana, Bianchini, Diletta, Zafeiriou, Zafeiris, Sideris, Spyridon, Ferreira, Ana, Figueiredo, Ines, Sumanasuriya, Semini, Mateo, Joaquin, Perez-Lopez, Raquel, Sharp, Adam, Tunariu, Nina, de Bono, Johann S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995869/
https://ncbi.nlm.nih.gov/pubmed/29911685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euo.2018.02.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak